As of Mar 2018
DWTI Product Pipeline
※1 The domestic pharmaceutical company have option rights in the whole world except Japan of H-1129, now the company is evaluating.
※2 K-134 has been targeted arteriosclerosis obliterans as indication, developed and completed phase 2 by Kowa Company, Ltd.. Meanwhile, Kowa is now considering another target disease.
544KB（Enlarge the above diagram）
GLANATEC® ophthalmic solution 0.4% ▶Learn more
WP-1303(H-1129) ▶Learn more
H-1337 ▶Learn more
K-134 ▶Learn more
DW-1002 ▶Learn more
Japan Innovative Therapeutics, Inc. Product Pipeline
108KB（Enlarge the above diagram）